Spero Therapeutics, Inc.SPRONASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank70
Studio
Year-over-Year Change

Cash generated from core business operations

Latest
$-27.67M
↑ 31% vs avg
Percentile
P70
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-39.98M
Historical baseline
PeriodValueYoY Change
TTM$-27.67M-18.0%
2024$-23.44M+28.9%
2023$-32.99M-326.8%
2022$-7.73M+88.0%
2021$-64.35M+25.1%
2020$-85.87M-71.7%
2019$-50.02M-26.2%
2018$-39.63M-1.3%
2017$-39.11M-35.1%
2016$-28.96M-